Steve is a co-founder and the CEO of Arrivo BioVentures, LLC, a drug development company. He has over 25 years of experience in the pharma/biotech industry with and a track record of successful fund raising, product licensing and M&A with start-up companies. Most recently, Steve was CEO of Velo Bio, a start-up company with a drug in development for severe preeclampsia. Velo was sold to AMAG Pharmaceuticals in 2018. Prior to Velo, he was co-founder, President and COO of Aerial BioPharma LLC, a drug development company that sold its lead drug for narcolepsy to Jazz Pharmaceuticals in 2014. Prior to Aerial, Steve was co-founder and Executive Vice President of Neuronex Inc, acquired by Acorda Therapeutics in December 2012. Additionally, he was an original member of the executive team at Addrenex Pharmaceuticals and played a key role in the company’s sale to Shionogi Pharma in 2009. He has also served as Vice President of Sales & Marketing at BioBehavioral Diagnostics Company, as well as assignments at Eli Lilly and Company and Braintree Laboratories.

Steve is currently a member of the Board of Directors and on the Audit Committee of Areteia Therapeutics. He is also on the Board of Directors of Knopp Biosciences and Otologic Pharmaceutics.

Steve holds a BS degree in Business Administration from the University of North Carolina at Chapel Hill and an MBA from the Kenan-Flagler School of Business at the University of North Carolina at Chapel Hill.

Bruce currently serves as the President & CEO of Neurvati Neurosciences, a Blackstone Life Sciences company. He brings deep-rooted, wide-ranging experience to this role spanning clinical neuropsychiatry, biotechnology equity research, healthcare investment banking, and drug development. Across his many roles in academia, clinical medicine, financial services, and industry, Bruce has maintained a passion for knowledge and serving patients and families in need.

A physician by training and neuropsychiatrist by specialty, Bruce completed residency training in Neurology and Psychiatry at New York Presbyterian Hospital and Weill Cornell Medical College and is a Diplomate of the American Board of Psychiatry and Neurology. Bruce served as Director of Clinical Neuropsychiatry at Weill Cornell Medical College and maintains a voluntary faculty appointment in the Department of Psychiatry. Previously, Bruce was a Partner at PJT Partners where he provided M&A and capital markets advisory services to biotechnology companies. He also held roles in equity research and investment banking at Goldman Sachs and Credit Suisse, respectively.

Bruce is a Co-founder and Senior Advisor of Click Therapeutics, a biotechnology company developing software as prescription medical therapeutics. He serves as a member of the Scientific Advisory Committee for the Daedelus Fund for Innovation at Weill Cornell Medical College, as a member of the Life Science Institute Leadership Council and Michigan Drug Discovery Advisory Board at The University of Michigan, and as a Business Advisory Board member at FOXG1 Research Foundation.

Dave Co-Founded Solas BioVentures based upon the desire to bring much needed innovation to the patient’s bedside. This patient centric focus came from his long academic medical career providing care and solutions to leverage the healthcare equation of Value = Quality /Cost. He has operated a startup MedTech, co-founded a large regional medical specialty group, as well as grown angel investing into a full fledge venture fund targeting MedTech, pharma, diagnostics, and special healthcare situations. Dave was the Southeast Medical Device Association member of the year in 2017. He has served on Life Science Tennessee Association Board previously. He is a widely published author with over 100 articles and a frequent speaker to academic venues throughout the U.S. and E.U. He retired as professor emeritus from the University of Tennessee College of Medicine in the Department of Obstetrics and Gynecology. His prior board experience is notable for Veran Medical acquired by Olympus Medical, NxThera acquired by Boston Scientific, Aegea Medical acquired by Cooper Surgical, and Aerial BioPharma acquired by Jazz Pharmaceuticals. Besides serving on the board of Arrivo BioPharma he serves on Veranex Solutions, Francis Medical, Knopp BioSciences, Intershunt Technologies, and Vesalio.

Dave earned a BS in Biology from Morehead State University, a MD from The Joan C Edwards School of Medicine of Marshall University, Residency in Obstetrics & Gynecology from The University of Florida, Maternal Fetal Medicine from Wake Forest University, and an MBA from The Gary W. Rollins College of Business of The University of Tennessee Chattanooga.

Bobby serves as Managing Director for Orlando Health Ventures (OHV), the corporate investment arm of Orlando Health. Prior to OHV, Bobby was Managing Director for Rex Health Ventures and has worked in corporate development at BlueCross BlueShield Tennessee along with prior positions at Citigroup and KPMG.

Currently Bobby serves on the Board of Directors of B-Secur Technologies, Vesalio and Emergo Therapeutics as well as serving as a Board Observer for 410 Medical, Bio 54 and Vergent Biosciences.

Bobby holds a BS in Finance from the University of Notre Dame and an International MBA from the Moore School of Business at University of South Carolina.

Chris is the Head of Corporate Development at Jazz Pharmaceuticals, where he has been a member of the Corporate Development team since 2012 and has worked on over $10B in total transactions across neuroscience and oncology during his time there. Prior to Jazz, he worked in a variety of operational roles at Azur Pharma and started his career at Deloitte, focused on life science and non-profit clients. Chris holds a bachelor’s degrees in accounting and finance from The Ohio State University.